Triple negative breast cancers (TNBCs) account for 10-20% of breast cancers and generally affect younger patient populations (<50 years) as well as African-American/Hispanic women.1,2 Current treatment options consist of surgical resection and radiation/chemical therapy; however, many of the drugs used are not cancer cell specific and result in widespread toxicity throughout body systems. A number of novel, small organic molecules selective towards cancer cells by inhibition of monocarboxylate transporters (MCT) were developed under the direction of Dr. Venkatram Mereddy. These compounds analogous to Alpha-cyano-4-hydroxycinnamic acid (CHC, a known MCT inhibitor) were synthesized from readily-available reagents and show high potential as lead compounds based on in vitro and in vivo studies.
University Honors Capstone Project Paper, University of Minnesota Duluth, 2015.
Synthesis and Testing of MCT1 and MCT4 Inhibiting Compounds as Novel Cancer Therapeutics.
Retrieved from the University of Minnesota Digital Conservancy,
Content distributed via the University of Minnesota's Digital Conservancy may be subject to additional license and use restrictions applied by the depositor.